The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C
Open accessAbstract
Treatment of chronic hepatitis C with Interferon (IFN) α2b monotherapy results in 10% to 15% sustained virological response (SVR). Combining IFN with ribavirin increases this response. In this analysis, using the Markov model, 6 treatment strategies for chronic hepatitis C (previously untreated) were compared on the basis of incremental cost per additional quality-adjusted life years ($/QALY). Our results showed that the no treatment strategy was associated with a cost of $38,747 and 13.10 QALYs. The strategy using IFN alone for 48 weeks was associated with a cost of $35,642 and 14.05 QALYs. The strategy using IFN monotherapy followed by combination therapy for nonresponders and relapsers was associated with a cost of $34,561 and 15.53 QALYs. A similar strategy, but limiting combination to relapsers only, was associated with a cost of $34,758 and 14.40 QALYs. The strategy using IFN with ribavirin as the initial therapy for all patients was associated with a cost of $34,792 and 15.31 QALYs. Finally, the strategy using viral genotyping first and then adjusting the duration of combination therapy based on genotype was associated with a cost of $37,263 and 15.89 QALYs. The strategy using genotyping to guide duration of combination therapy was the most cost-effective approach with an incremental cost-effectiveness ratio of $7,500 per QALY. Sensitivity analyses confirmed the robustness of these results. We conclude that combination of IFN and ribavirin with duration of therapy based on the viral genotype, is a cost-effective approach in treating patients with chronic hepatitis C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Cited by
The global burden of hepatitis C
Lavanchy, D. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01934.x · Cited by 1,368
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
Razavi, H., ElKhoury, A. C., Elbasha, E., Estes, C., Pasini, K., Poynard, T., & Kumar, R. (2013) · Hepatology · doi:10.1002/hep.26218 · Cited by 474
Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., et al. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12248 · Cited by 477
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Self-citationHealth-state utilities and quality of life in hepatitis C patients
Chong, C. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)06054-9 · Cited by 277
Metadata
- Authors
- Younossi, Z. M., Singer, M. E., McHutchison, J. G., & Shermock, K. M.
- Venue
- Hepatology
- Published
- 1999-11
- Volume
- 30
- Issue
- 5
- Pages
- 1318-1324
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2085684927
- Cited by
- 160
- References
- 1
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C. https://app.cochat.ai/papers/10.1002/hep.510300518
- The paper
- Younossi, Z. M., Singer, M. E., McHutchison, J. G., & Shermock, K. M. (1999). Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. https://doi.org/10.1002/hep.510300518
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.